Known targets — ChEMBL curated mechanism
APH1AAPH1BNCSTNPSEN1PSEN2PSENEN
The experimentally established mechanism targets of Semagacestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 known ✓ | P49768 | 19/20 | 1.00 |
| ▸ | PSEN2 known ✓ | P49810 | 19/20 | 1.00 |
| ▸ | APH1B known ✓ | Q8WW43 | 19/20 | 1.00 |
| ▸ | NCSTN known ✓ | Q92542 | 19/20 | 1.00 |
| ▸ | APH1A known ✓ | Q96BI3 | 19/20 | 1.00 |
| ▸ | PSENEN known ✓ | Q9NZ42 | 19/20 | 1.00 |
| ▸ | XIAP | P98170 | 1/20 | 0.69 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Semagacestat SCHEMBL12050112 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Semagacestat SCHEMBL29353755 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Semagacestat SCHEMBL13387771 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Semagacestat SCHEMBL14876852 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Semagacestat SCHEMBL30579757 | 0.99 | PSEN1 (0.98) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Semagacestat SCHEMBL1812166 | 0.99 | PSEN1 (0.98) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21577575 | 0.90 | PSEN1 (0.81) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18301563 | 0.86 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7849704 | 0.85 | XIAP (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4537099 | 0.85 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3970725-B1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2025-08-20 | — | — | EP | claimed |
| US-12161647-B2 | Treating hearing loss | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2024-12-10 | — | — | US | claimed |
| EP-3970725-A1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | Massachusetts Eye & Ear Infirmary (US) | 2022-03-23 | — | — | EP | claimed |
| EP-2892506-B1 | TREATING HEARING LOSS WITH THE GAMMA-SECRETASE INHIBITOR LY411575 | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2021-11-03 | — | — | EP | claimed |
| US-20210299138-A1 | Treating Hearing Loss | MASSACHUSETTS EYE & EAR INFIRMARY | 2021-09-30 | — | — | US | claimed |
| US-20190091234-A1 | GAMMA-SECRETASE INHIBITION REDUCE APOC3 LEVELS AND PLASMA TRIGLYCERIDES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-28 | — | — | US | claimed |
| US-20180369253-A1 | Treating Hearing Loss | MASSACHUSETTS EYE AND EAR INFIRMARY | 2018-12-27 | — | — | US | claimed |
| US-10149855-B2 | Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-12-11 | — | — | US | claimed |
| US-9572815-B2 | Methods and compositions of p27KIP1 transcriptional modulators | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-02-21 | — | — | US | claimed |
| US-20160354382-A1 | GAMMA-SECRETASE INHIBITION REDUCE APOC3 LEVELS AND PLASMA TRIGLYCERIDES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-12-08 | — | — | US | claimed |
| US-20150209367-A1 | Treating Hearing Loss | MASSACHUSETTS EYE & EAR INFIRMARY | 2015-07-30 | — | — | US | claimed |
| US-8883502-B2 | Expandable cell source of neuronal stem cell populations and methods for obtaining and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-11 | — | — | US | claimed |
| US-8299059-B2 | Crystalline compound and a process for its preparation | ELI LILLY AND COMPANY (US) | 2012-10-30 | — | — | US | claimed |
| US-20110105471-A1 | NOVEL CRYSTALLINE COMPOUND AND A PROCESS FOR ITS PREPARATION | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | claimed |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-12584105-B2 | Autologous cell replacement therapy for Parkinson's disease | THE MCLEAN HOSPITAL CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3458076-B1 | HUMAN AIRWAY STEM CELLS IN LUNG EPITHELIAL ENGINEERING | MASSACHUSETTS GEN HOSPITAL (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20070299053-A1 | Lactam compound | ELI LILLY AND COMPANY | 2007-12-27 | — | — | US | disclosed |
| US-20070299053-A1 | Lactam compound | ELI LILLY AND COMPANY | 2007-12-27 | — | — | US | disclosed |
| EP-1341531-B1 | LACTAM COMPOUND TO INHIBIT BETA-AMYLOID PEPTIDE RELEASE OR SYNTHESIS | LILLY CO ELI (US) | 2007-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299138-A1 | Treating Hearing Loss | BACE1, BACE2, PSENEN | PSEN1 9/4885PSEN2 10/4885APH1B 4/4885 |
| US-20160354382-A1 | GAMMA-SECRETASE INHIBITION REDUCE APOC3 LEVELS AND PLASMA TRIGLYCERIDES | BACE1, APOB, BACE2 | PSEN1 15/4885PSEN2 22/4885APH1B 7/4885 |
| US-12584105-B2 | Autologous cell replacement therapy for Parkinson's disease | SNCA, PARK7, NES | PSEN1 348/4885PSEN2 251/4885APH1B 3730/4885 |
| US-12161647-B2 | Treating hearing loss | BACE1, BACE2, PSENEN | PSEN1 9/4885PSEN2 10/4885APH1B 4/4885 |
| US-10149855-B2 | Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides | BACE1, APOB, BACE2 | PSEN1 15/4885PSEN2 22/4885APH1B 7/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | PSEN1 1744/4885PSEN2 2511/4885APH1B 2583/4885 |
| US-20110105471-A1 | NOVEL CRYSTALLINE COMPOUND AND A PROCESS FOR ITS PREPARATION | CA2, CA4, CACNA1B | PSEN1 1910/4885PSEN2 894/4885APH1B 1042/4885 |
| US-20070299053-A1 | Lactam compound | AAAS, ORMDL3, NAALAD2 | PSEN1 739/4885PSEN2 430/4885APH1B 9/4885 |
| US-20150209367-A1 | Treating Hearing Loss | BACE1, BACE2, PSENEN | PSEN1 9/4885PSEN2 10/4885APH1B 4/4885 |
| US-20180369253-A1 | Treating Hearing Loss | BACE1, BACE2, PSENEN | PSEN1 9/4885PSEN2 10/4885APH1B 4/4885 |
| US-20190091234-A1 | GAMMA-SECRETASE INHIBITION REDUCE APOC3 LEVELS AND PLASMA TRIGLYCERIDES | BACE1, APOB, BACE2 | PSEN1 15/4885PSEN2 22/4885APH1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.